FGFR1 amplification in squamous cell carcinoma of the lung.
FGFR1 amplification in squamous cell carcinoma of the lung.
复制标题
DOI：
10.1097/jto.0b013e31826aed28
复制
发表时间：
2012-12
期刊：
影响因子：
--
通讯作者：
Iafrate AJ
中科院分区：
文献类型：
--
作者：
Heist RS;Mino-Kenudson M;Sequist LV;Tammireddy S;Morrissey L;Christiani DC;Engelman JA;Iafrate AJ
FGFR1的扩增在鳞状细胞肺癌中已有报道，并可能成为治疗的分子靶点。然而，人们对FGFR1扩增的临床和人口统计学相关性知之甚少。这项研究是一项机构审查委员会批准的对2005-2011年在马萨诸塞州综合医院(MGH)看到的226名鳞状细胞肺癌患者的回顾分析。获得了所有患者的临床和人口学特征，以及包括手术、放疗和化疗在内的治疗细节，以及总体存活率。对福尔马林固定石蜡包埋的肿瘤组织行FISH检测FGFR1。临床基因分型结果也进行了复习。226例鳞状细胞肺癌患者中37例(16%)扩增阳性，采用基因扩增与拷贝数控制比=2.2的定义。FGFR1扩增状态与年龄、性别、分期、鳞状细胞内组织学亚型、吸烟史或吸烟年限无关。我们发现总体上FGFR1扩增状态在总存活率上没有显著差异；在晚期亚组中，由于样本量较小，我们的研究结果并不确定。在16%的鳞状细胞肺癌患者的临床队列中发现了FGFR1扩增。缺乏与FGFR1扩增相关的任何特定的临床人口学特征，这表明所有鳞状细胞患者都应该进行这种基因组变化的检测。
Amplification of FGFR1 has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification. The study is an institutional review board-approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital (MGH) from 2005–2011. Clinical and demographic characteristics were obtained on all patients, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. FISH was performed for FGFR1 on formalin fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available. 37 of 226 (16%) patients with squamous cell lung cancer were positive for amplification using a definition of amplification of a gene to copy number control ratio >/= 2.2. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive due to the small sample size. FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancer patients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cell patients should be tested for this genomic change.